In a study of HAS administration in patients with cirrhosis and infections other than SBP, patients receiving albumin were less likely than controls to develop new bacterial infections during the follow-up period (9.8% vs. 24.6%, respectively; p < 0.03) [11]. The gene discussed is ALB; the disease is infection.